| Date: | 10/28/2024 |
|-------------------------------|-------------------------------------------------------------------------------------------|
| Your Name: | Caitlin M. Terao |
| Manuscript Title: | Identifying cognitive test scores associated with early tau burden in Alzheimer's disease |
| Manuscript Number (if known): | DADM-D-24-00356 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | e all entities with whom you have this onship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| | | Time frame: Since the initial planning | of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | Click the tab key to add additional rows. |
| | | Time frame: past 36 month | S |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None | |
| 3 | Royalties or licenses | None | |

| | | Name all entities with whom you have thisSpecifications/Comments (e.g., if payrelationship or indicate none (add rows as needed)made to you or to your institution) | /ments were |
|----|-----------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|
| 4 | Consulting fees | ☑ None | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None | |
| 6 | Payment for expert testimony | ☑ None □ □ □ □ □ □ | |
| 7 | Support for attending meetings and/or travel | ☑ None □ □ □ □ □ □ □ □ | |
| 8 | Patents planned, issued or pending | ☑ None □ □ □ □ □ □ □ □ | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None | |

| | | | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|-----------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| 11 | Stock or stock options | | None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | | None | |
| 13 | Other financial or non-financial interests | | None | |
| Plea × | Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form. | | | |

| Date: | 11/14/2024 |
|-------------------------------|---------------------------------------------------------------------------------------|
| Your Name: | Madeline Wood Alexander |
| Manuscript Title: | Identifying cognitive test scores to predict early tau burden in Alzheimer's disease. |
| Manuscript Number (if known): | DADM-D-24-00356 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | e all entities with whom you have this onship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| | | Time frame: Since the initial planning | of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | Click the tab key to add additional rows. |
| | | Time frame: past 36 month | S |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None | |
| 3 | Royalties or licenses | None | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|-----------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| 4 | Consulting fees | ☑ None | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | ☑ None | |
| 6 | Payment for expert testimony | None | |
| 7 | Support for attending meetings and/or travel | None WHRC Travel Award (2024), CCNA Travel Award (2024), AAIC Travel Fellowship (2023), CIHR IGH Travel Award for OSSD (2023) | |
| 8 | Patents planned, issued or pending | None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None | |

| | | | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|-----------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| 11 | Stock or stock options | | None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | | None | |
| 13 | Other financial or non-financial interests | | None | |
| Plea × | Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form. | | | |

| Date: | 11/14/2024 |
|-------------------------------|-------------------------------------------------------------------------------------------|
| Your Name: | R. Philip Chalmers |
| Manuscript Title: | Identifying cognitive test scores associated with early tau burden in Alzheimer's disease |
| Manuscript Number (if known): | DADM-D-24-00356 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | e all entities with whom you have this onship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| | | Time frame: Since the initial planning | of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | Click the tab key to add additional rows. |
| | | Time frame: past 36 month | S |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None | |
| 3 | Royalties or licenses | None | |

| | | Name all entities with whom you have thisSpecifications/Comments (e.g., if payrelationship or indicate none (add rows as needed)made to you or to your institution) | /ments were |
|----|-----------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|
| 4 | Consulting fees | ☑ None | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None | |
| 6 | Payment for expert testimony | ☑ None □ □ □ □ □ □ | |
| 7 | Support for attending meetings and/or travel | ☑ None □ □ □ □ □ □ □ □ | |
| 8 | Patents planned, issued or pending | ☑ None □ □ □ □ □ □ □ □ | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None | |

| | | | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|-----------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| 11 | Stock or stock options | | None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | | None | |
| 13 | Other financial or non-financial interests | | None | |
| Plea × | Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form. | | | |

| Date: | 11/10/2024 |
|-------------------------------|-------------------------------------------------------------------------------------------|
| Your Name: | Silina Z. Boshmaf |
| Manuscript Title: | Identifying cognitive test scores associated with early tau burden in Alzheimer's disease |
| Manuscript Number (if known): | DADM-D-24-00356 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | | e all entities with whom you have this onship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|----------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| | Time frame: Since the initial planning of the work | | | of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | | None | Click the tab key to add additional rows. |
| | | | Time frame: past 36 month | S |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | | None | |
| 3 | Royalties or licenses | | None | |

| | | Name all entities with whom you have thisSpecifications/Comments (e.g., if payrelationship or indicate none (add rows as needed)made to you or to your institution) | /ments were |
|----|-----------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|
| 4 | Consulting fees | ☑ None | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None | |
| 6 | Payment for expert testimony | ☑ None □ □ □ □ □ □ | |
| 7 | Support for attending meetings and/or travel | ☑ None □ □ □ □ □ □ □ □ | |
| 8 | Patents planned, issued or pending | ☑ None □ □ □ □ □ □ □ □ | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None | |

| | | | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|--|-----------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| 11 | Stock or stock options | | None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | | None | |
| 13 | Other financial or non-financial interests | | None | |
| Please place an "X" next to the following statement to indicate your agreement: | | | | |

| Date: | 11/9/2024 |
|-------------------------------|-------------------------------------------------------------------------------------------|
| Your Name: | Jane Paterson |
| Manuscript Title: | Identifying cognitive test scores associated with early tau burden in Alzheimer's disease |
| Manuscript Number (if known): | DADM-D-24-00356 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | e all entities with whom you have this onship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| | | Time frame: Since the initial planning | of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | Click the tab key to add additional rows. |
| | | Time frame: past 36 month | S |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None | |
| 3 | Royalties or licenses | None | |

| | | Name all entities with whom you have thisSpecifications/Comments (e.g., if payrelationship or indicate none (add rows as needed)made to you or to your institution) | /ments were |
|----|-----------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|
| 4 | Consulting fees | ☑ None | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None | |
| 6 | Payment for expert testimony | ☑ None □ □ □ □ □ □ | |
| 7 | Support for attending meetings and/or travel | ☑ None □ □ □ □ □ □ □ □ | |
| 8 | Patents planned, issued or pending | ☑ None □ □ □ □ □ □ □ □ | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None | |

| | | | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|--|-----------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| 11 | Stock or stock options | | None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | | None | |
| 13 | Other financial or non-financial interests | | None | |
| Please place an "X" next to the following statement to indicate your agreement: | | | | |

| Date: | 9/9/2024 |
|-------------------------------|-----------------------------------------------------------------------------------------------------------------------|
| Your Name: | Sandra E. Black |
| Manuscript Title: | Identifying cognitive test scores that predict neocortical tau pathology associated with early Alzheimer's disease |
| Manuscript Number (if known): | Click or tap here to enter text. |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | | Time frame: Since the initial planning | of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | ⊠ None | Click the tab key to add additional rows. |
| | | Time frame: past 36 month | S |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None Contract Research: Genentech, Optina, Roche, Eli Lilly, Eisa/Biogen Idec, NovoNordisk, Lilly Avid, ICON Peer Reviewed: Ontario Brain Institute, CIHR, Leducq Foundation, Heart and Stroke Foundation of Canada, NIH, Alzheimer's Drug Discovery Foundation, Brain Canada, Weston Brain Institute, Condian Dartmership for Stroke Becouvery | Payments made to Institution. No personal investigator fees taken including Eli Lilly. Payments made to Institution. No personal investigator fees taken. |
| | | Canadian Partnership for Stroke Recovery, Canadian Foundation for Innovation, Focused Ultrasound Foundation, Alzheimer's Association US, Queen's University, Compute Canada Resources for Research Groups, | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-----------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|
| | | CANARIE, Networks of Centres of Excellence of Canada | |
| 3 | Royalties or licenses | None | |
| 4 | Consulting fees | None Roche Biogen NovoNordisk Eisai Eli Lilly | Payments made to mePayments made to mePayments made to mePayments made to mePayments made to me |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None Biogen Roche New England Journal Manuscript Roche Models of Care Analysis in Canada in Submission Eisai MRI Workshop Cpdnetwork planning committee for AD educational program | Payments made to me No Payments to me Payments made to me for advising and manuscript review Payments made to me Payments made to me |
| 6 | Payment for expert testimony | ⊠ None | |
| 7 | Support for attending meetings and/or travel | ⊠ None | |
| 8 | Patents planned, issued or pending | None | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) | |
|------|---------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|--|
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None Conference Board of Canada World Dementia Council University of Rochester Contribution to the Mission and Scientific Leadership of the Small Vessel VCID Biomarker Validation Consortium National Institute of Neurological Disorders and Stroke, Ontario Dementia Care Alliance (ODCA) | Advisory Boards only. No personal fees taken. | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | ⊠ None | | |
| 11 | Stock or stock options | ⊠ None | | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | ⊠ None | | |
| 13 | Other financial or non-financial interests | ⊠ None | | |
| Plea | Please place an "X" next to the following statement to indicate your agreement: | | | |

| Date: | 11/12/2024 |
|-------------------------------|-------------------------------------------------------------------------------------------|
| Your Name: | Kathryn Papp |
| Manuscript Title: | Identifying cognitive test scores associated with early tau burden in Alzheimer's disease |
| Manuscript Number (if known): | DADM-D-24-00356 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | | e all entities with whom you have this onship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|----------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| | | | Time frame: Since the initial planning | of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | R01/ | None AG084017-01A1 | Click the tab key to add additional rows. |
| | | | Time frame: past 36 month | S |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | | None | |
| 3 | Royalties or licenses | | None | |

| | | Name all entities with whom you have thisSpecifications/Comments (e.g., if payrelationship or indicate none (add rows as needed)made to you or to your institution) | /ments were |
|----|-----------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|
| 4 | Consulting fees | ☑ None | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None | |
| 6 | Payment for expert testimony | ☑ None □ □ □ □ □ □ | |
| 7 | Support for attending meetings and/or travel | ☑ None □ □ □ □ □ □ □ □ | |
| 8 | Patents planned, issued or pending | ☑ None □ □ □ □ □ □ □ □ | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None | |

| | | | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|-----------|-------------------------------------------------------------------------------------------------|--|-----------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| 11 | Stock or stock options | | None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | | None | |
| 13 | Other financial or non-financial interests | | None | |
| Plea × | Please place an "X" next to the following statement to indicate your agreement: | | | |

| Date: | 11/18/2024 | |
|-------------------------------|-------------------------------------------------------------------------------------------|--|
| Your Name: | Reisa A. Sperling | |
| Manuscript Title: | Identifying cognitive test scores associated with early tau burden in Alzheimer's disease | |
| Manuscript Number (if known): | DADM-D-24-00356 | |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| | | Time frame: Since the initial planning o | of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for | None National Institutes of Health | P01AG036694 funding to institution |
| | this item. | | |
| | | Time frame: past 36 months | |
| 2 | Grants or contracts from | □ None | |
| | any entity (if not | Alzheimer's Association | To Institution |
| | indicated in item | National Institute on Aging | To Institution |
| | #1 above). | GHR Foundation | To Institution |
| | | | Research funding to clinical trial sites |
| | | Eisai | Research funding to clinical trial sites |
| 3 | Royalties or licenses | None | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---------------------------------|----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| 4 | Consulting fees | □ None | |
| | | AbbVie | Paid directly as consultant |
| | | AC Immune | Paid directly as consultant |
| | | Acumen | Paid directly as consultant |
| | | Alector | Paid directly as consultant |
| | | Apellis | Paid directly as consultant |
| | | Biohaven | Paid directly as consultant |
| | | Bristol Myers Squibb | Paid directly as consultant |
| | | Genentech | Paid directly as consultant |
| | | Janssen | Paid directly as consultant |
| | | Nervgen | Paid directly as consultant |
| | | Oligomerix | Paid directly as consultant |
| | | Prothena | Paid directly as consultant |
| | | Roche | Paid directly as consultant |
| | | Vigil Neuroscience | Paid directly as consultant |
| | | lonis | Paid directly as consultant |
| | | Vaxxinity | Paid directly as consultant |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| 5 | Payment or honoraria for | ⊠ None | |
| | lectures, | | |
| | presentations, speakers | | |
| | bureaus, | | |
| | manuscript | | |
| | writing or | | |
| | educational | | |
| | events | | |
| 6 | Payment for expert testimony | ⊠ None | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | □ None | |
| 7 | Support for attending | | |
| 7 | | Alzheimer's Association | Reimbursement for travel |
| 7 | attending | Alzheimer's Association Clinical Trials in Alzheimer's Disease | Reimbursement for travel Reimbursement for hotel and airfare |
| 7 | attending meetings and/or | | |

| | | | all entities with whom you have this nship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---------------------------------------------------------------------------------------------------------------------|--|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| 8 | Patents planned, issued or pending | | None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | | None | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | | None | |
| 11 | Stock or stock options | | None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | | None | |
| 13 | Other financial or non-financial interests | | None | |
| | Please place an "X" next to the following statement to indicate your agreement: | | | |

| Date: | 11/12/2024 |
|-------------------------------|-------------------------------------------------------------------------------------------|
| Your Name: | Jennifer Rabin |
| Manuscript Title: | Identifying cognitive test scores associated with early tau burden in Alzheimer's disease |
| Manuscript Number (if known): | DADM-D-24-00356 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| | | Time frame: Since the initial planning o | of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None | Click the tab key to add additional rows. |
| | | Time frame: past 36 months | 5 |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None CIHR, NSERC, Alzheimer's Society of Canada, Alzheimer's Association, Donald T. Stuss Young Investigator Research Innovation Award, University of Toronto (Temerty-Tanz-TDRA, Slamen-Fast) | All payments made to Sunnybrook Research Institute |
| 3 | Royalties or licenses | ☑ None | |

| | | ame all entities with whom you have this Specifications/Comments (e.e. all entities or indicate none (add rows as needed) made to you or to your institutions and the second seco | |
|----|-----------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|
| 4 | Consulting fees | None | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None | |
| 6 | Payment for expert testimony | None | |
| 7 | Support for attending meetings and/or travel | None | |
| 8 | Patents planned, issued or pending | None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | None | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None | |

| | | | e all entities with whom you have this ionship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|-----------|-------------------------------------------------------------------------------------------------|--|-----------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| 11 | Stock or stock options | | None | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | | None | |
| 13 | Other financial or non-financial interests | | None | |
| Plea × | Please place an "X" next to the following statement to indicate your agreement: | | | |